Pulmonary Arterial Hypertension - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 214
Inquire Before Buying

Global Markets Direct's, ‘Pulmonary Arterial Hypertension - Pipeline Review, H2 2016', provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension

  • The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects

  • The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Pulmonary Arterial Hypertension - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Pulmonary Arterial Hypertension Overview 9
Therapeutics Development 10
Pipeline Products for Pulmonary Arterial Hypertension - Overview 10
Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis 11
Pulmonary Arterial Hypertension - Therapeutics under Development by Companies 12
Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes 15
Pulmonary Arterial Hypertension - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pulmonary Arterial Hypertension - Products under Development by Companies 19
Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes 23
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 24
Actelion Ltd 24
APT Therapeutics, Inc. 25
Arena Pharmaceuticals, Inc. 26
Ascendis Pharma A/S 27
AVEO Pharmaceuticals, Inc. 28
Bial - Portela & Ca, S.A. 29
Celsion Corporation 30
Celtaxsys, Inc. 31
Chugai Pharmaceutical Co., Ltd. 32
Complexa, Inc. 33
Eli Lilly and Company 34
Galectin Therapeutics, Inc. 35
Gilead Sciences, Inc. 36
Hanmi Pharmaceuticals, Co. Ltd. 37
HitGen LTD 38
Insmed Incorporated 39
INVENT Pharmaceuticals, Inc. 40
Johnson & Johnson 41
Kowa Company, Ltd. 42
Mast Therapeutics, Inc. 43
Mezzion Pharma Co. Ltd. 44
miRagen Therapeutics, Inc. 45
Morphogen-IX Limited 46
Nippon Kayaku Co., Ltd. 47
Nippon Shinyaku Co., Ltd. 48
Novartis AG 49
Peloton Therapeutics, Inc. 50
PhaseBio Pharmaceuticals, Inc. 51
Pluristem Therapeutics Inc. 52
Proteo, Inc. 53
Pulmokine, Inc. 54
Reata Pharmaceuticals, Inc. 55
Respira Therapeutics, Inc. 56
Reviva Pharmaceuticals Inc. 57
Selten Pharma, Inc 58
Silence Therapeutics Plc 59
SteadyMed Therapeutics, Inc. 60
Suda Ltd 61
Toray Industries, Inc. 62
Pulmonary Arterial Hypertension - Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Target 64
Assessment by Mechanism of Action 68
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 76
acebilustat - Drug Profile 76
Antibody for Pulmonary Arterial Hypertension - Drug Profile 79
Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile 80
APT-602 - Drug Profile 81
AV-353 - Drug Profile 82
bardoxolone methyl - Drug Profile 83
beraprost sodium ER - Drug Profile 87
beraprost sodium SR - Drug Profile 88
BIA-51058 - Drug Profile 89
BMP-10 - Drug Profile 90
BMP-9 - Drug Profile 91
CTX-3397 - Drug Profile 92
CXA-10 - Drug Profile 93
Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile 95
GMA-301 - Drug Profile 96
GMCT-01 - Drug Profile 97
GRMD-02 - Drug Profile 101
HGP-1207 - Drug Profile 112
INS-1009 - Drug Profile 113
INV-240 - Drug Profile 115
JNJ-26993135 - Drug Profile 116
KAR-5585 - Drug Profile 117
macitentan - Drug Profile 118
MFC-1040 - Drug Profile 123
MFC-2040 - Drug Profile 124
Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile 125
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 126
PB-1046 - Drug Profile 127
PB-1120 - Drug Profile 129
PF-543 - Drug Profile 130
pitavastatin NP - Drug Profile 131
PK-10453 - Drug Profile 132
PK-10571 - Drug Profile 133
PLX-PAD - Drug Profile 134
PT-2977 - Drug Profile 142
QCC-374 - Drug Profile 143
R-190 - Drug Profile 144
ralinepag - Drug Profile 146
RP-5063 - Drug Profile 148
RT-234 - Drug Profile 150
selexipag - Drug Profile 151
selonsertib - Drug Profile 155
sirolimus albumin-bound - Drug Profile 156
Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile 158
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 159
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 160
Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension - Drug Profile 161
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 162
sodium nitrite - Drug Profile 163
SPI-054 - Drug Profile 166
SPI-183 - Drug Profile 167
SUD-004 - Drug Profile 168
Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile 169
tacrolimus - Drug Profile 170
tadalafil - Drug Profile 171
tiprelestat - Drug Profile 173
tocilizumab - Drug Profile 177
TR-422 - Drug Profile 185
treprostinil - Drug Profile 186
treprostinil diolamine - Drug Profile 187
ubenimex - Drug Profile 189
udenafil - Drug Profile 191
Pulmonary Arterial Hypertension - Dormant Projects 194
Pulmonary Arterial Hypertension - Discontinued Products 198
Pulmonary Arterial Hypertension - Product Development Milestones 199
Featured News & Press Releases 199
Appendix 209
Methodology 209
Coverage 209
Secondary Research 209
Primary Research 209
Expert Panel Validation 209
Contact Us 209
Disclaimer 210

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2016 14
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Development by Companies, H2 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Development, H2 2016 22
Products under Development by Companies, H2 2016 23
Products under Development by Companies, H2 2016 (Contd..1) 24
Products under Development by Companies, H2 2016 (Contd..2) 25
Products under Development by Companies, H2 2016 (Contd..3) 26
Products under Investigation by Universities/Institutes, H2 2016 27
Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H2 2016 28
Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H2 2016 29
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 30
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016 31
Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 32
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2016 33
Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H2 2016 34
Pulmonary Arterial Hypertension - Pipeline by Celtaxsys, Inc., H2 2016 35
Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 36
Pulmonary Arterial Hypertension - Pipeline by Complexa, Inc., H2 2016 37
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2016 38
Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016 39
Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H2 2016 40
Pulmonary Arterial Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 41
Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H2 2016 42
Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H2 2016 43
Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 44
Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2016 45
Pulmonary Arterial Hypertension - Pipeline by Kowa Company, Ltd., H2 2016 46
Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics, Inc., H2 2016 47
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 48
Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2016 49
Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Limited, H2 2016 50
Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H2 2016 51
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 52
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2016 53
Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics, Inc., H2 2016 54
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 55
Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2016 56
Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H2 2016 57
Pulmonary Arterial Hypertension - Pipeline by Pulmokine, Inc., H2 2016 58
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 59
Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics, Inc., H2 2016 60
Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 61
Pulmonary Arterial Hypertension - Pipeline by Selten Pharma, Inc, H2 2016 62
Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016 63
Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H2 2016 64
Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2016 65
Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H2 2016 66
Assessment by Monotherapy Products, H2 2016 67
Number of Products by Stage and Target, H2 2016 69
Number of Products by Stage and Mechanism of Action, H2 2016 73
Number of Products by Stage and Route of Administration, H2 2016 77
Number of Products by Stage and Molecule Type, H2 2016 79
Pulmonary Arterial Hypertension - Dormant Projects, H2 2016 198
Pulmonary Arterial Hypertension - Dormant Projects (Contd..1), H2 2016 199
Pulmonary Arterial Hypertension - Dormant Projects (Contd..2), H2 2016 200
Pulmonary Arterial Hypertension - Dormant Projects (Contd..3), H2 2016 201
Pulmonary Arterial Hypertension - Discontinued Products, H2 2016 202

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2016 14
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 20
Comparative Analysis by Clinical Stage Development, H2 2016 21
Comparative Analysis by Early Stage Products, H2 2016 22
Assessment by Monotherapy Products, H2 2016 67
Number of Products by Top 10 Targets, H2 2016 68
Number of Products by Stage and Top 10 Targets, H2 2016 68
Number of Products by Top 10 Mechanism of Actions, H2 2016 72
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 72
Number of Products by Routes of Administration, H2 2016 76
Number of Products by Stage and Routes of Administration, H2 2016 76
Number of Products by Top 10 Molecule Types, H2 2016 78
Number of Products by Stage and Top 10 Molecule Types, H2 2016 78
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Hypertension - Pipeline Review, H1 2017
    Published: 13-Jun-2017        Price: US 2000 Onwards        Pages: 547
    Hypertension - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H1 2017, provides an overview of the Hypertension (Cardiovascular) pipeline landscape. Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water......
  • Hypertension Drugs Industry Forecasts - China Focus
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 109
    This study focuses on China's Hypertension Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. ......
  • Hypertension Drugs Companies in China
    Published: 15-May-2017        Price: US 1800 Onwards        Pages: 54
    This study focuses on China's Hypertension Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions ......
  • Hypertension Drugs Markets in China
    Published: 15-May-2017        Price: US 4000 Onwards        Pages: 215
    China's demand for Hypertension Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, in......
  • Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021
    Published: 12-Apr-2017        Price: US 3500 Onwards        Pages: 70
    PAH in the arteries, which carry blood from the heart to the lungs, occurs when blood vessels become narrow, making blood flow difficult. The analysts forecast global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021. Covered in this report This report covers the present scenario and the growth prospects of the global pulmonary arterial hypertension drugs market for 2017-2021. To calculate the market siz......
  • EMEA (Europe, Middle East and Africa) Nitrendipine Market Report 2017
    Published: 10-Apr-2017        Price: US 4000 Onwards        Pages: 102
    In this report, the EMEA Nitrendipine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (MT), revenue (Million USD), market share and growth rate of Nitrendipine for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux; - Middle Ea......
  • Global Hypertension Partnering 2010 to 2017
    Published: 01-Apr-2017        Price: US 1495 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the hypertension partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. • Trends in partnering deals • Top deals by valu......
  • United States Nitrendipine Market Report 2017
    Published: 31-Mar-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Nitrendipine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Nit......
  • Global Nifedipine Sales Market Report 2017
    Published: 30-Mar-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the global Nifedipine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Nifedipine for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeast ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs